Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337364 | 0.90 | LMNA (0.45) | LMNASMN1; SMN2 | |
| SCHEMBL336767 | 0.90 | LMNA (0.45) | LMNASMN1; SMN2 | |
| SCHEMBL8699188 | 0.77 | HTT (0.48) | LMNASMN1; SMN2HTTGAAKEAP1 | |
| SCHEMBL19437432 | 0.75 | LMNA (0.47) | LMNASMN1; SMN2L3MBTL1HTTGAA | |
| SCHEMBL20697084 | 0.74 | LMNA (0.61) | LMNASMN1; SMN2L3MBTL1HTTMAPT | |
| SCHEMBL19448421 | 0.74 | ITGB3 (0.43) | LMNASMN1; SMN2HTTMAPTMEN1 | |
| SCHEMBL20913878 | 0.74 | ITGB3 (0.43) | LMNASMN1; SMN2HTTMAPTMEN1 | |
| SCHEMBL22035074 | 0.73 | LMNA (0.57) | LMNASMN1; SMN2L3MBTL1HTTMAPT | |
| SCHEMBL25568627 | 0.73 | LMNA (0.60) | LMNASMN1; SMN2L3MBTL1HTTMAPT | |
| SCHEMBL25568624 | 0.73 | SYK (0.50) | LMNASMN1; SMN2L3MBTL1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | LMNA 4741/4885SMN1; SMN2 1949/4885L3MBTL1 2706/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | LMNA 4741/4885SMN1; SMN2 1949/4885L3MBTL1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.